Newscasts - Pfizer wins $10 billion Metsera bidding war as Novo Nordisk exits

Metsera

08/11/2025 13:14

Click the following link to watch video: https://share.newscasts.refinitiv.com/link?entryId=1_x29mig5d&referenceId=tag:reuters.com,2025:newsml_RW049508112025RP1_930&pageId=Newscasts
Source: 'Reuters - Business videos'

Description: U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk. Fiona Jones reports. 

Short Link: https://lseg.group/47v754J

Video Transcript:

US drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera. It ended the biotech bidding war with Danish rival Novo Nordisk, which announced Saturday it would exit the race. Metsera accepted a sweetened offer from Pfizer late Friday. It cited US antitrust risks in Novo's bid that it had previously called "superior." Novo said in a statement that it believed its offer structure was compliant with antitrust laws. Metsera's drugs are projected to reach $5 billion in peak sales, and this win hands Pfizer a way into the lucrative obesity drug market, even if Metsera's treatments remain years away from hitting shelves. It marks a blow for Novo as it tries to claw back lost ground against US rival Eli Lilly. The Danish drug maker later said it's advancing its own pipeline of treatment options for obesity and that it would continue to assess opportunities for business development and acquisitions. Pfizer said it expects to close the merger soon after Metsera's November 13 shareholder meeting.